Understanding preclinical and clinical immunogenicity risks in novel biotherapeutics development

Zuben E. Sauna(Center for Biologics Evaluation and Research), Narendra Chirmule(Symphony Technology (United States)), Vibha Jawa(EpiVax (United States)), Sathy V. Balu‐Iyer(University at Buffalo, State University of New York)
Frontiers in Immunology
May 12, 2023
10.3389/fimmu.2023.1151888
Cited by 20

Related Papers

Immunogenicity assessment of AAV-based gene therapies: An IQ consortium industry white paper
|Molecular Therapy — Methods & Clinical Development|2022|113
2020 White Paper on Recent Issues in Bioanalysis: Vaccine Assay Validation, qPCR Assay Validation, QC for CAR-T Flow Cytometry, NAb Assay Harmonization and ELISpot Validation ( <u>Part 3</u> –Recommendations on Immunogenicity Assay Strategies, NAb Assays, Biosimilars and FDA/EMA Immunogenicity Guidance/Guideline, Gene &amp; Cell Therapy and Vaccine Assays)
|Bioanalysis|2021|60
Assay format diversity in pre-clinical immunogenicity risk assessment: Toward a possible harmonization of antigenicity assays
|mAbs|2021|57
2018 White Paper on Recent Issues in Bioanalysis: Focus on Flow Cytometry, Gene Therapy, Cut Points and Key Clarifications on Bav (Part 3 – Lba/Cell-Based Assays: Immunogenicity, Biomarkers and Pk Assays)
|Bioanalysis|2018|53
Evaluation of the Humoral Response to Adeno-Associated Virus-Based Gene Therapy Modalities Using Total Antibody Assays
|The AAPS Journal|2021|52